Skip to main content
. 2015 Aug 27;30(1):102–110. doi: 10.1096/fj.15-275891

Figure 5.

Figure 5.

Inhibition of SPHK1 activity rescues endothelial barrier disruption in TRPC1-null ECs and lungs. A) Dose–response curve of SPHK1 inhibitor, SK1-I in altering TER. SK1-I was added onto WT or TRPC1-null ECs after stable baseline was achieved. Plot shows means ± sd of changes in TER values normalized to TER values at time zero. *Values different from WT ECs; P < 0.05. B) SK1-I treatment rescues thrombin-induced barrier dysfunction in TRPC1-null ECs. Thrombin was added after 2 h treatment with 20 μM SK1-I. *Values different from WT ECs; P < 0.05.